Braf Kinase Inhibitors Market Is Estimated To Witness High Growth
The Braf kinase inhibitors market is driven by increasing prevalence of various cancers globally. For instance, according to WHO estimates, cancer burden is expected to grow to 27.5 million new cases and 16.3 million cancer deaths by 2040. Additionally, approval and launch of new products is also expected to fuel market growth over the forecast period. For example, in July 2018, Pfizer initiated a phase 3 clinical trial for encorafenib plus cetuximab in previously treated patients with metastatic colorectal cancer. However, high costs associated with cancer treatment and side effects of Braf kinase inhibitors such as rash, fatigue and diarrhea pose a challenge to market growth.
The global Braf Kinase Inhibitors market is expected to witness high growth, exhibiting CAGR of 8.6% over the forecast period, due to increasing incidence of melanomas globally. According to American Cancer Society, over 100,000 new melanoma cases are diagnosed each year in the US.
North America is expected to dominate the global Braf Kinase Inhibitors market over the forecast period. This is attributed to the rising melanoma case numbers in the US and Canada along with high adoption of premium-priced targeted therapies in the region. The market in Asia Pacific is projected to exhibit the fastest growth led by China and India, owing to growing healthcare spending and increasing awareness.
Key players operating in the Braf Kinase Inhibitors market are F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc. Roche leads the market with Zelboraf (vemurafenib) being one of the first approved BRAF inhibitors. Other major players are continuously investing in developing novel combination regimens to address resistance issue and expand indications of existing drugs.
Read More
https://healthcarelatesteditionnews.blogspot.com/2023/11/combination-therapies-drives-braf.html
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian